|
NCI: Posted on Wednesday, February 29, 2012 7:08 PM
Name of the TrialPhase III Randomized Study of Early Local Therapy Comprising Surgery versus Standard Palliative Therapy for the Intact Primary Tumor in Patients with Stage IV Breast Cancer (ECOG-E2108). See the protocol summary.Dr. Seema Khan Principal InvestigatorDr. Seema Khan, Eastern Cooperative Oncology Group
Why This Trial Is ImportantWomen diagnosed with breast cancer that has already spread (metastasized) to other parts of the body are usually treated with systemic therapy, which may include chemotherapy, |
|
|
NCI: Posted on Saturday, December 31, 2011 5:37 PM
|
|
NCI/ Nwaokai: Posted on Wednesday, December 14, 2011 12:24 AM
|
|
Komen Foundation: Posted on Tuesday, October 11, 2011 6:11 PM
T-DM1 Produces Promising Results Against Advanced HER2-Positive Breast CancerAmong women with metastatic, HER2-positive breast cancer, trastuzumab emtansine (T-DM1)—an investigational drug that combines Herceptin® (trastuzumab) and a chemotherapy drug—resulted in better progression-free survival than standard chemotherapy and Herceptin.For more click HERE
FOR MORE ON BREAST CANCER BUY THE BOOK 'MEMOIRS OF CANCER," LOADED WITH MEDICAL CANCER FACTS. NOW, FOR NEW SALE PRICE OF ONLY $12. |
|
|
Nwaokai-Beecham: Posted on Sunday, October 09, 2011 6:49 PM
CLICKHER TO SEE AN ANIMATION; BREAST CANCER PROGRESSION AND STAGING ANIMATION: ALSO:
ANIMATION OF BREAST CANCER PROGRESSION AND STAGING AND...
MASTECTOMY SURGERY VIDEO AND...
HOW TO RECOGNIZE BREAST CANCER SYMPTOMS VIDEO AND. |
|
|
NCI: Posted on Wednesday, October 05, 2011 5:47 PM
A combination of two available cancer drugs could offer a new treatment option for hormonal therapy, researchers said last week at a scientific meeting in Stockholm, Sweden. In a phase III clinical trial, women who received the combination lived for a median of 11 months without the disease progressing, compared with about 4 months for |
|
|
Komen Foundation: Posted on Monday, October 03, 2011 8:44 PM
We have a new Susan G. Komen page of information. This month find out where and when the Komen Foundation will host Races for the Cure. See what is new with the Komen Foundation. Check out the news on "Pink Ribbon, Red Ribbon," and Stories of Inspiration. CLICK HERE Remember, if you want more information on cancer, buy the book "Memoirs of Cancer" complete with medical information from 2 expert oncologist. HERE |
|
|
NCI: Posted on Tuesday, September 20, 2011 8:53 PM
studies. Young age at diagnosis is thought to be a risk factor for disease recurrence, and many young women with breast cancer choose mastectomy for treatment. The research was presented at the |
|
|
NCI: Posted on Tuesday, September 20, 2011 8:36 PM
Mutations in the BRCA1 gene are known to increase a woman’s lifetime risk of developing breast and ovarian cancers, but researchers are still investigating how the protein encoded by this gene helps suppress the formation of tumors. A study by Dr. Inder Verma and his colleagues at the Salk Institute for Biological Studies in the September 8 Nature offers some clues.Using mice and human breast cancer cells, the researchers identified a series of |
|
|
National Breast Cancer Foundation, inc.: Posted on Monday, August 29, 2011 9:57 PM
Breast cancer type is categorized by whether it begins in the ducts or lobules, the organs responsible for breast milk production. Understanding the specific type of breast cancer can help you ask better questions and work with your physicians to get the best breast cancer treatments.
Ductal Carcinoma In-Situ (DCIS)
Infiltrating Ductal Carcinoma (IDC)
Medullary Carcinoma
Infiltrating Lobular Carcinoma (ILC)
Tubular Carcinoma
Mucinous Carcinoma (Colloid)
Inflammatory Breast Cancer (IBC) For more information on the types and |
|
